Adaptimmune Therapeutics PLC
Market Movers (8-K)
Adaptimmune Therapeutics plc announced its voluntary delisting from The Nasdaq Capital Market and subsequent deregistration to reduce costs and maximize value from remaining assets.
Worse than expected
Adaptimmune Therapeutics plc received a Nasdaq notice for failing to meet the minimum bid price requirement, with a deadline of December 1, 2025, to regain compliance.
Delay expected
Worse than expected
Adaptimmune Therapeutics plc received a Nasdaq notice for failing to meet the minimum Market Value of Listed Securities requirement, initiating a 180-day compliance period.
Worse than expected
Adaptimmune Therapeutics plc announced the appointment of Christopher Hill as its new Chief Financial Officer, effective September 10, 2025, under a consulting agreement.
Adaptimmune Therapeutics plc disclosed the termination of its Chief Financial Officer, Gavin Wood, and Chief Patient Supply Officer, John Lunger, due to redundancy, detailing their severance packages.
Worse than expected
Delay expected
Adaptimmune Therapeutics PLC announced the departure of its Chief Commercial Officer, Cintia Piccina, due to redundancy, with a severance package of $473,800.
Quarterly Earnings (10-Q)
Adaptimmune Therapeutics PLC reported a significant net loss and reduced revenue for Q2 2025, driven by a major asset sale and subsequent workforce restructuring.
Capital raise
Worse than expected
Adaptimmune Therapeutics reports Q1 2025 results, highlighting TECELRA's commercial launch but also raising concerns about its ability to continue as a going concern due to significant net losses and negative cash flows.
Capital raise
Worse than expected
Adaptimmune Therapeutics announced its Q3 2024 results, marked by the launch of Tecelra, a strategic restructuring, and significant revenue from collaboration agreements.
Better than expected
Capital raise
Adaptimmune Therapeutics saw a significant increase in revenue in the second quarter of 2024, primarily due to a contract modification related to the termination of its collaboration with Genentech.
Better than expected
Capital raise
Adaptimmune Therapeutics reported its first quarter 2024 results, highlighting a decrease in revenue due to the termination of a collaboration agreement, while preparing for the commercial launch of afami-cel.
Worse than expected
Capital raise
Annual Reports (10-K)
Adaptimmune Therapeutics focuses on TECELRA's commercial launch and strategic restructuring to prioritize core programs.
Capital raise
Worse than expected
Adaptimmune Therapeutics' 10-K filing details the company's securities, governance, and operational strategies as it transitions to a commercial-stage cell therapy company.
Capital raise
Insider Trading (Form 4)
Adaptimmune Therapeutics PLC's Chief Financial Officer, Gavin Wood, sold 96,000 ordinary shares, eliminating his direct beneficial ownership of shares held as ADSs.
Adaptimmune Therapeutics PLC's Chief Operating Officer, William C. Bertrand Jr., sold 207,000 ordinary shares on August 28, 2025.
Worse than expected
Adaptimmune Therapeutics PLC Director Ali Behbahani, through affiliated entities, has fully divested his indirect beneficial ownership of the company's ordinary shares.
Worse than expected
EcoR1 Capital, a 10% owner and director of Adaptimmune Therapeutics PLC, reported the sale of over 64 million Ordinary Shares through pre-arranged Rule 10b5-1 plans across three days in late July 2025.
Worse than expected
William C. Bertrand Jr., Chief Operating Officer of Adaptimmune Therapeutics PLC, acquired options to purchase ordinary shares in the company on February 20, 2025.
Form 4: Adaptimmune Therapeutics PLC: Chief Scientific Officer Acquires Options to Purchase Ordinary Shares
Joanna Elizabeth Brewer, Chief Scientific Officer of Adaptimmune Therapeutics PLC, reports the acquisition of options to purchase ordinary shares in the company.
Proxy Statements (Def-14A)
Adaptimmune Therapeutics announces its 2025 Annual General Meeting to be held on May 29, 2025, in Abingdon, Oxfordshire, U.K.
Adaptimmune Therapeutics announces its Annual General Meeting (AGM) will be held on May 14, 2024, to vote on director re-elections, auditor appointments, executive compensation, and share allotment authorizations.
Capital raise
Schedule 13D - Activist Investments
New Enterprise Associates funds significantly reduced their beneficial ownership in Adaptimmune Therapeutics Plc through recent open market sales.
Worse than expected
Schedule 13G - Passive Investments
Long Focus Capital Management and John Helmers have reported a 0% beneficial ownership stake in Adaptimmune Therapeutics PLC as of December 31, 2025.
Two Seas Capital LP and its affiliates have reported a complete divestment of their holdings in Adaptimmune Therapeutics PLC, now owning 0% of the company's ordinary shares.
Worse than expected
EcoR1 Capital and its affiliates have reduced their beneficial ownership in Adaptimmune Therapeutics PLC to below 5% of the outstanding Ordinary Shares.
Worse than expected
Two Seas Capital LP and its affiliates have increased their beneficial ownership in Adaptimmune Therapeutics PLC to 8.5% of ordinary shares as of June 30, 2025.
Two Seas Capital LP, along with its general partner and chief investment officer, has reported a passive 8% beneficial ownership stake in Adaptimmune Therapeutics PLC.
Two Seas Capital LP, along with its general partner Two Seas Capital GP LLC and managing member Sina Toussi, has disclosed a passive 5.8% beneficial ownership stake in Adaptimmune Therapeutics PLC.